Asaf Danziger

2018

In 2018, Asaf Danziger earned a total compensation of $4.6M as Chief Executive Officer at NovoCure, a 6% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$644,266
Option Awards$2,359,400
Salary$692,675
Stock Awards$587,505
Other$286,448
Total$4,570,294

Danziger received $2.4M in option awards, accounting for 52% of the total pay in 2018.

Danziger also received $644.3K in non-equity incentive plan, $692.7K in salary, $587.5K in stock awards and $286.4K in other compensation.

Rankings

In 2018, Asaf Danziger's compensation ranked 2,296th out of 14,244 executives tracked by ExecPay. In other words, Danziger earned more than 83.9% of executives.

ClassificationRankingPercentile
All
2,296
out of 14,244
84th
Division
Manufacturing
838
out of 5,759
85th
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
98
out of 849
89th
Industry group
Surgical, Medical, And Dental Instruments And Supplies
46
out of 547
92nd
Industry
Surgical and Medical Instruments and Apparatus
24
out of 348
93rd
Source: SEC filing on April 10, 2019.

Danziger's colleagues

We found five more compensation records of executives who worked with Asaf Danziger at NovoCure in 2018.

2018

William Doyle

NovoCure

Chairman

2018

Wilhelmus Groenhuysen

NovoCure

Chief Financial Officer

2018

Eilon Kirson

NovoCure

Chief Scientific Officer

2018

Pritesh Shah

NovoCure

Chief Commercial Officer

2018

Michael Ambrogi

NovoCure

Chief Operating Officer

News

In-depth

You may also like